Based in San Francisco, Hims & Hers Health, Inc. (HIMS) operates a consumer-centric telehealth platform providing personalized health and wellness solutions. Launched in 2017, the company focuses on subscription-based services and retail partnerships across numerous therapeutic categories, generating revenue through both online subscriptions and wholesale channels.
The stock currently holds a Zacks Rank #1 (Strong Buy), complemented by a B grade for both its Momentum and overall VGM (Value, Growth, Momentum) Style Scores. While shares have seen a recent pullback of 8.5% over the past week, they remain up 13.4% over the last four weeks and have surged 134% in the past year. Trading activity has also been robust, with an average of 33,722,048 shares traded daily over the last 20 sessions.
Beyond price action, the company’s earnings outlook is a key driver of its momentum. In the last 60 days, one analyst has revised their earnings estimate for fiscal 2025 upward. Consequently, the Zacks Consensus Estimate for the year has risen by $0.02 to $0.75 per share. HIMS also has a track record of outperforming expectations, boasting an average earnings surprise of 19.6%.
Given its strong earnings growth, a top-tier Zacks Rank, and favorable Momentum and VGM scores, HIMS presents a noteworthy profile for investors focused on momentum strategies.
Source link
